Recent Trading Session
Eli Lilly (LLY) ended the recent trading session at $797.48, demonstrating a -0.3% swing from the preceding day’s closing price. The stock fell short of the S&P 500, which registered a gain of 0.16% for the day. On the other hand, the Dow registered a gain of 0.86%, and the technology-centric Nasdaq decreased by 0.38%.
Past Month Performance
The drugmaker’s stock has climbed by 1.37% in the past month, exceeding the Medical sector’s loss of 5.3% and the S&P 500’s loss of 2.2%.
Earnings Outlook
The investment community will be paying close attention to the earnings performance of Eli Lilly in its upcoming release. The company’s upcoming EPS (Earnings Per Share) is projected at $5.43, signifying a 118.07% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $13.93 billion, up 48.94% from the year-ago period.
Monitoring Analyst Projections
Furthermore, it would be beneficial for investors to monitor any recent shifts in analyst projections for Eli Lilly. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, upbeat changes in estimates indicate analysts’ favorable outlook on the company’s business health and profitability.
Utilizing Zacks Rank
Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system spans from #1 (Strong Buy) to #5 (Strong Sell), with a noteworthy track record of outperforming since 1988. Stocks rated #1 produce an average annual return of +25%. Within the past 30 days, our consensus EPS projection has moved 0.49% higher. As of now, Eli Lilly holds a Zacks Rank of #3 (Hold).
Valuation Analysis
Looking at its valuation, Eli Lilly is holding a Forward P/E Ratio of 15.2, reflecting its current stock price relative to its projected earnings for the next 12 months. This ratio indicates that investors are currently valuing the company based on these expectations.
Industry Standing
Eli Lilly operates in the pharmaceuticals industry, with a market capitalization of $60 billion as of recent reporting. The company has a strong reputation due to its commitment to innovation and customer-centric solutions, which have driven significant growth over the years.
Key Components Driving Performance
- Product Innovation: Eli Lilly is known for introducing groundbreaking drugs that address critical medical needs.
- Market Expansion: The company has successfully expanded its operations into emerging markets, enhancing global reach.
- R&D Focus: A substantial portion of Eli Lilly’s revenue comes from research and development activities.
Additional Resources
For more information on Eli Lilly, please visit our website or follow us on social media for the latest updates.
